{
    "body": "What is the mechanism of action of eprotirome?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22784847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22542282", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24440706", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23776891", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23565368", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20872316", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20935564", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24731671", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25172631", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20220185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20625286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18447589"
    ], 
    "ideal_answer": [
        "Eprotirome belongs to thyromimetics and has selective TR\u03b21 activity. It has shown to be effective in dyslipidemia by the lipid-lowering action of TH in the liver and also in obesity."
    ], 
    "type": "summary", 
    "id": "54f1e4d0c409818c32000002", 
    "snippets": [
        {
            "offsetInBeginSection": 456, 
            "offsetInEndSection": 537, 
            "text": "Eprotirome and Sobetirome are 2 thyromimetics that have selective TR\u03b21 activity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565368", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1136, 
            "offsetInEndSection": 1355, 
            "text": "Recently, the development of the most promising agent in this class, eprotirome, was halted over toxicology concerns following long-term canine studies. Consequently, the future of contemporary TR\u03b2 agonists is unclear. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22784847", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 196, 
            "offsetInEndSection": 348, 
            "text": "We designed novel thyromimetics with high receptor (TR\u03b2) and organ (liver) selectivity based on the structure of eprotirome (3) and molecular modeling. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22542282", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 985, 
            "offsetInEndSection": 1163, 
            "text": "In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic-pituitary-thyroid feedback.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935564", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 434, 
            "offsetInEndSection": 658, 
            "text": "This review details recent advances in the development of TR\u03b2 subtype- and liver-selective STRM analogs, and presents the results of preliminary clinical trials with one of these compounds, eprotirome (KB-2115; Karo Bio AB).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872316", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1424, 
            "offsetInEndSection": 1564, 
            "text": "Examples of synthetic analogues are GC-1 (or sobetirome) and KB2115 (or eprotirome) which show ipolipidaemic and antiaterogenic capacities. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 345, 
            "offsetInEndSection": 555, 
            "text": "METHODS: The history of thyromimetics in atherosclerosis and dyslipidaemia is reviewed as the background to the recent publication of the first human data on a new selective thyromimetic, KB-2115 (eprotirome). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447589", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 451, 
            "offsetInEndSection": 532, 
            "text": " Eprotirome and Sobetirome are 2 thyromimetics that have selective TR\u03b21 activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565368", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 456, 
            "offsetInEndSection": 535, 
            "text": "Eprotirome and Sobetirome are 2 thyromimetics that have selective TR\u03b21 activity", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23565368", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 891, 
            "offsetInEndSection": 976, 
            "text": "We also examined the effects of the TR\u03b2 agonist eprotirome on hepatic gene regulation", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440706", 
            "endSection": "abstract"
        }
    ]
}